|
|
Vaccine Detail
|
Self-Adjuvanting Pam2CysSK4-MUC1(27-mer)-diTn Vaccine ± PADRE |
| Vaccine Information |
- Vaccine Name: Self-Adjuvanting Pam2CysSK4-MUC1(27-mer)-diTn Vaccine ± PADRE
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Conjugate vaccine
- Status: Research
- Host Species for Licensed Use: Mouse
- Antigen: 27-mer MUC1 (AHGVTSAPDTRPAPGSTAPPAHGVTSA), Tn at T10, S16 (McDonald et al., 2018)
- Immunization Route: subcutaneous injection
- Description: A self-adjuvanting glycolipopeptide conjugate vaccine composed of a 27-mer MUC1 VNTR glycopeptide (AHGVTSAPDTRPAPGSTAPPAHGVTSA) bearing two Tn antigens (GalNAc-α) at the Thr residue of the PDTR epitope and the Ser residue of the GSTA epitope, covalently linked through a triethylene glycolate spacer to the TLR2 agonist Pam2CysSK4. The construct was synthesized by diselenide–selenoester ligation (DSL) followed by deselenization. In C57BL/6 mice, subcutaneous vaccination with 5 nmol induced MUC1-specific CTL activity (~20% specific lysis; p = 0.011), representing the first reported CTL induction by a single-agent self-adjuvanting MUC1 vaccine without external adjuvant or surfactant formulation. The vaccine elicited MUC1-specific IgM but no IgG class switching, attributed to the absence of a conjugated T-cell helper epitope. Serum antibodies bound MUC1-expressing MCF-7 human breast cancer cells by flow cytometry. Admixture with PADRE increased IgM titers and elevated IFN-γ, IL-2, IL-17A, IL-6, and IL-22, suggestive of a mixed helper T-cell response, but still did not induce IgG class switching (McDonald et al., 2018).
|
| Host Response |
|
|
| References |
McDonald et al., 2018: McDonald DM, Hanna CC, Ashhurst AS, Corcilius L, Byrne SN, Payne RJ. Synthesis of a Self-Adjuvanting MUC1 Vaccine via Diselenide-Selenoester Ligation-Deselenization. ACS chemical biology. 2018; 13(12); 3279-3285. [PubMed: 30359529].
|
|
